- Also Known As:
- Circulating Tumor Cell (CTC) Count
- Circulating Tumor DNA (ctDNA)
At a Glance
When to Get Tested?
Your healthcare practitioner will indicate whether this type of testing is medically appropriate and consider other options.
A blood sample drawn from a vein
Test Preparation Needed?
No test preparation is typically needed. However, your healthcare practitioner will tell you if you should alter any medications that you are taking prior to having your blood drawn.
What is being tested?
Researchers have known for some time that tumors shed cells and DNA or RNA into body fluids, including blood. In recent years, scientists have been able to gain information about tumors by analyzing these cells or DNA or RNA that circulate in the blood. These techniques require blood samples rather than the tumor tissue samples required by traditional biopsies, so they are often called liquid biopsies.
Tissue biopsies are the standard of care for cancer diagnosis. However, removing cancer tissue through surgery, or in some cases a needle biopsy, is an invasive process. In addition, the difficulty reaching a tumor can limit the ability of healthcare practitioners to sample it. However, the genetic information in tumor cells and tumor DNA or RNA may provide important information about the tumor, such as the likelihood of response to treatment, of relapse after treatment, or how the tumor is responding to cancer therapy. This has led to the emergence of liquid biopsy as a promising, non-invasive, complement to tissue biopsy.
By requiring a blood draw rather than a tissue biopsy, liquid biopsies can be more tolerable than traditional biopsies and may be acceptable for more frequent sampling to monitor cancer. As cancer treatments become more targeted to the genetic makeup of a tumor, liquid biopsies are a minimally-invasive way to understand how a tumor’s genetic make-up is evolving during treatment.
Currently, there are two main approaches to liquid biopsy:
- Circulating tumor cell (CTC) tests, which look at whole tumor cells in the blood
- Circulating tumor DNA (ctDNA) tests, which look for the DNA that tumor cells release into the blood
Other techniques, such as looking at cell fragments called extracellular vesicles (exosomes) or small molecules of non-coding RNA (microRNAs), are being studied.
In addition to applications such as cancer detection and treatment, liquid biopsies may also provide promise for cancer diagnosis, monitoring, and early detection. Currently, the medical applications of liquid biopsies are limited to determining prognosis in breast, colon, and prostate cancer, guiding treatment in those cancers, and guiding treatment of non-small cell lung cancer.
How is the test used?
Liquid biopsies may be used to help guide treatment, predict treatment response or prognosis, and monitor therapy and disease progression in select cancers.
There are currently two main types of clinically available liquid biopsy:
- Circulating tumor cell count (CTC)—these tests look at whole tumor cells in the blood to help determine prognosis in breast, colon, or prostate cancer that has spread to nearby or distant organs (metastatic). They may also be used to evaluate responses to therapy for those cancers.
- Circulating tumor DNA (ctDNA)—these tests look for tumor DNA that cancer cells release into the blood. An example is an FDA-approved test that is used to decide if anti-EGFR medications (erlotinib or osimertinib) can be used to treat non-small-cell lung cancer.
When is it ordered?
Testing may be ordered:
- When you have metastatic breast, colon, or prostate cancer and a better understanding of the prognosis (predicted course of disease) is necessary to guide treatment
- When monitoring response to treatment for metastatic breast, colon, or prostate cancer
- Before or after starting certain specific targeted therapies for non-small cell lung cancer
What does the test result mean?
- Circulating tumor cell count (CTC)—circulating tumor cell counts are measured as the number of CTCs in a specified volume of blood. Results may be interpreted as favorable or unfavorable. Prostate, colon, and breast cancers all have unique cutoffs for when a CTC count is no longer favorable for prognosis.Studies show that lower CTC counts or levels are associated with a more favorable prognosis, specifically how long individuals live after treatment (overall survival) and the time between diagnosis and progression of the disease to a higher stage or recurrence of the tumor (progression-free survival). If the CTC count is above a certain cutoff during the course of cancer, it is associated with a poor prognosis and is predictive of shorter progression-free survival and overall survival. If it is below that cutoff it is associated with more favorable prognosis.
- Circulating tumor DNA (ctDNA) tests—these tests can detect mutations in the tumor that can predict potential responsiveness or resistance to certain therapies. For example:
- In a person with lung cancer, a positive ctDNA test for a sensitizing EGFR mutation (i.e., a mutation that makes the cancer sensitive to targeted therapy) means the cancer is likely to respond to targeted therapy and the individual can receive these treatments. However, ctDNA testing is known to sometimes give false-negative results (meaning the mutation is present but not detected by the ctDNA testing). For this reason, the FDA recommends a tissue biopsy if the liquid biopsy is negative (doesn’t detect a sensitizing mutation).
- In addition, when a patient has already been treated with an EGFR-targeted tyrosine kinase inhibitor but does not appear to be responding favorably to the treatment, a liquid biopsy may be used to detect an EGFR T790M mutation, which causes resistance to targeted therapy. If an EGFR T790M mutation is detected, it can then be targeted with a different drug that has been designed especially for this particular mutation. However, data are currently limited on this use for a liquid biopsy, so it may be used only if a tissue biopsy cannot be obtained.
How widely available are liquid biopsies?
While liquid biopsies continue to become commercially available and in some cases are FDA-approved, more research is needed to understand the benefits and limitations of these tests. For example, it is still unclear if using liquid biopsies to guide treatment actually improves outcomes for people with cancer.
Liquid biopsies are currently most useful in detecting mutations that predict response or resistance to treatment in lung cancer and for evaluating prognosis in select cancers. Over time, these tests may become a part of management of a wider array of cancers. Liquid biopsies are also showing promise as cancer screening tools in research settings, but none are currently FDA-approved as screening tests.
Some experts say that more research is needed before liquid biopsies are used in medical practice. In March 2018, a review jointly published by the American Society of Clinical Oncology and the College of American Pathologists concluded that currently, cell-free tumor DNA tests are not useful outside of clinical trials. The groups say that prospective studies are needed to evaluate how well liquid biopsies perform in diagnosing cancer, but such studies have not yet been conducted. The experts acknowledge, however, that research on these tests is progressing quickly and use of liquid biopsies will likely evolve in the near future.
If I get a liquid biopsy, will I still need a tissue biopsy?
For diagnosis of your tumor, you will need a conventional tissue biopsy. As mentioned above, if your liquid biopsy is negative for certain mutations, you may need to have follow-up testing done on a conventional biopsy specimen. A liquid biopsy may miss details available from a conventional tissue biopsy and can’t determine where in one’s body a mutation has arisen.
In some situations, a liquid biopsy alone can provide sufficient information for making treatment decisions. It may be sufficient if, for example, the primary test is positive for a mutation or if a T790M mutation is detected and a tissue biopsy cannot be obtained. While liquid biopsies are promising and powerful tools, they complement but do not necessarily replace tissue biopsies for the foreseeable future.
How long does it take for results?
Turn-around times vary for this test, depending on the lab performing it and the type of liquid biopsy test. Not all labs perform these tests and your sample may need to be sent to a specialized reference laboratory. Typically, the test results aren’t ready for several days and may take more than a week to become available.
(2015 June). Circulating Tumor Cell Count. ARUP Laboratories. Available online at http://ltd.aruplab.com/Tests/Pdf/177. Accessed June 2019.
Ornes, S. (2016 March 26). A Blood Test for Cancer. Cancer Today. Available online at https://www.cancertodaymag.org/Pages/Spring2016/A-Blood-Test-for-Cancer-Liquid-Biopsies.aspx. Accessed June 2019.
(2016 July 12). Seeking Cancer Clues in Blood, Researchers Explore Exomes. National Cancer Institute. Available online at https://www.cancer.gov/about-cancer/diagnosis-staging/research/exosomes. Accessed June 2019.
Ilié, M. and Hoffman, P. (2016 August). Pros: Can tissue biopsy be replaced by liquid biopsy? Translational Lung Cancer Research. Available online at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009092/. Accessed June 2019.
(2016 December 24). Patient Report Example, EGFR T790M Mutation Detection in Circulating Tumor DNA by Digital Droplet PCR, Detected. ARUP Laboratories. Available online at http://ltd.aruplab.com/Tests/DownloadReport/2012868%2C%20Detected.pdf. Accessed June 2019.
Kwapisz, D. (2017 February). The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? Annals of Translational Medicine. Available online at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5326656/. Accessed June 2019.
(2017 April 6). Perakis, S. and Specicher, M. R. Emerging Concepts in Liquid Biopsies. BMC Medicine. Available online at https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-017-0840-6. Accessed June 2019.
(2017 April 27). Patient Report Example, Circulating Tumor Cell Count, Breast Cancer. ARUP Laboratories. Available online at http://ltd.aruplab.com/Tests/DownloadReport/0093399%2C%20Abnormal%20Breast.pdf. Accessed June 2019.
NCI Staff. (2017 November 8). Liquid Biopsy: Using DNA in Blood to Detect, Track, and Treat Cancer. National Cancer Institute. Available online at https://www.cancer.gov/news-events/cancer-currents-blog/2017/liquid-biopsy-detects-treats-cancer. Accessed June 2019.
(© 2018). EGFR T790M Mutation in Circulating Tumor DNA by Digital Droplet PCR. ARUP Laboratories. Available online at https://www.aruplab.com/T790M. Accessed June 2019.
(© 2019). Circulating Tumor Cell Count. ARUP Laboratories. Available online at http://ltd.aruplab.com/tests/pub/0093399. Accessed June 2019.
(© 2019). What is Liquid Biopsy? Hoffman-La Roche Ltd. Available online at https://www.roche.com/research_and_development/what_we_are_working_on/oncology/liquid-biopsy.htm. Accessed June 2019.
Rifai, Nader. (© 2018). Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 6th Edition: Elsevier, St. Louis, MO. Pp 1111-1144.
(© 1995-2019). Test ID: CTCPC, Circulating Tumor Cells (CTC) for Prostate Cancer by CellSearch, Blood. Mayo Medical Laboratories. Available online at https://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/35325. Accessed June 2019.
Liquid Biopsy Test Shows Promise for Detecting Early-Stage Colorectal Cancer. American Society of Clinical Oncology. Available online at https://www.asco.org/about-asco/press-center/news-releases/liquid-biopsy-test-shows-promise-detecting-early-stage. Accessed June 2019.
Bronner, M. Revolutionizing Treatment for Cancer Care: New Circulating Cell-Free Tumor DNA (ctDNA)Technology. ARUP Laboratories. Available online at https://www.aruplab.com/files/resources/news/ExpertEdge_Bronner.pdf. Accessed June 2019.
Samowitz, W. Breakthrough Technology Spurs New Test for Non-Small Cell Lung Cancer Patients. ARUP Laboratories. Available online at https://www.aruplab.com/files/resources/news/ExpertEdge_Samowitz.pdf. Accessed June 2019.
(March 5, 2018) Pam Harrison, Liquid Biopsies Not Yet Ready for Prime Time, Says Expert Review. Medscape Medical News. Available at https://www.medscape.com/viewarticle/893402?nlid=121175_1021&src=WNL_mdplsfeat_180313_mscpedit_path&uac=20899EN&spon=43&impID=1580533&faf=1. Accessed June 2019.
Merker J, et al., Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. DOI: 10.1200/JCO.2017.76.8671 Journal of Clinical Oncology 36, no. 16 (June 1 2018) 1631-1641. Published online March 05, 2018. Accessed June 2019.